The p21cip1/waf1 cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells

被引：95

作者：

Lincet, H

Poulain, L

Remy, JS

Deslandes, E

Duigou, F

Gauduchon, P

Staedel, C

机构：

[1] Ctr Reg Lutte Canc Francois Baclesse, Expt Cancerol Lab, INSERM, CJF 96 03, F-14076 Caen 05, France

[2] Ctr Reg Lutte Canc Francois Baclesse, Expt Cancerol Lab, INSERM, EA 1772, F-14076 Caen, France

[3] Fac Pharm Strasbourg, Lab Chim Genet, CNRS, UMR 7514, F-67401 Illkirch, France

[4] Ctr Francois Baclesse, Anat Pathol Lab, F-14076 Caen 05, France

来源：

CANCER LETTERS | 2000年 / 161卷 / 01期

关键词：

ovarian carcinoma; cdk-inhibitor p21(cip1); cisplatin; chemoresistance; apoptosis;

D O I：

10.1016/S0304-3835(00)00586-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The seriousness of ovarian cancer, which is related to the observed link between recurrency and cell cycle control defect, prompted us to explore the effect of ectopic expression of the cdk inhibitor p21(cip1/waf1) on ovarian carcinoma chemosensitivity. The transfection of p21(cip1/waf1) cDNA into SKOV3 and OVCAR3 cells led to reduction of tumor cell growth, enhanced susceptibility to cisplatin-induced apoptosis, and abolition of recurrency after cisplatin exposure. p21(cip1/waf1) gene transfer allowed a marked reduction of the cisplatin concentration needed to erradicate the tumor cell population. These results suggest exploring the possible use of p21(cip1/waf1) as an adjunctive to conventional chemotherapy. (C) 2000 Elsevier Science Ireland Ltd, All rights reserved.

引用

页码：17 / 26

页数：10

共 41 条

[11] INHIBITION OF CYCLIN-DEPENDENT KINASES BY P21 [J].

HARPER, JW ;

ELLEDGE, SJ ;

KEYOMARSI, K ;

DYNLACHT, B ;

TSAI, LH ;

ZHANG, PM ;

DOBROWOLSKI, S ;

BAI, C ;

CONNELLCROWLEY, L ;

SWINDELL, E ;

FOX, MP ;

WEI, N .

MOLECULAR BIOLOGY OF THE CELL, 1995, 6 (04) :387-400

[12] APOPTOSIS INDUCED BY ANTICANCER DRUGS [J].

HICKMAN, JA .

CANCER AND METASTASIS REVIEWS, 1992, 11 (02) :121-139

[13] P53 MUTATIONS IN HUMAN CANCERS [J].

HOLLSTEIN, M ;

SIDRANSKY, D ;

VOGELSTEIN, B ;

HARRIS, CC .

SCIENCE, 1991, 253 (5015) :49-53

[14] Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene [J].

Inoue, A ;

Narumi, K ;

Matsubara, N ;

Sugawara, S ;

Saijo, Y ;

Satoh, K ;

Nukiwa, T .

CANCER LETTERS, 2000, 157 (01) :105-112

[15]

Joshi US, 1998, CANCER GENE THER, V5, P183

[16]

KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207

[17]

McDonald E, 1996, CANCER RES, V56, P2250

[18]

Michieli P, 1996, ONCOGENE, V12, P775

[19]

MILNER BJ, 1993, CANCER RES, V53, P2128

[20]

Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0

← 1 2 3 4 5 →